Overview
NICE is unable to make a recommendation on vericiguat (Verquvo) for treating chronic heart failure with reduced ejection fraction in adults because Bayer did not provide an evidence submission.
Last reviewed: 29 September 2021
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.